The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | Clinical data for CD19-directed CAR T-cell products in ALL
Claire Roddie, MD, PhD, from University College London Hospitals NHS Foundation Trust, London, UK, explains how CD19-directed CAR T-cells is probably the biggest development in acute lymphoblastic leukemia (ALL) in a generation. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA), Dr Roddie goes on to discuss the recent updates from the ELIANA trial of tisagenlecleucel in R/R ALL and the remarkable outcomes seen in patients previously unresponsive to treatment (NCT02435849). She also highlights the difference in efficacy between younger and older ALL patients, and research into this therapy in the adult setting.
